Condition
Selected Advanced Solid Tumors
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Terminated1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT06877533Phase 1TerminatedPrimary
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
NCT03530397Phase 1Active Not RecruitingPrimary
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
Showing all 2 trials